Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review

BACKGROUND: PARP inhibitors (PARPi) have recently been approved for various malignancies based on the results of several clinical trials. However, these trials have mostly recruited patients with germline BRCA mutations, and it is unclear whether PARPi have similar efficacy in patients with somatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohyuddin, Ghulam Rehman, Aziz, Muhammad, Britt, Alec, Wade, Lee, Sun, Weijing, Baranda, Joaquina, Al-Rajabi, Raed, Saeed, Anwaar, Kasi, Anup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267765/
https://www.ncbi.nlm.nih.gov/pubmed/32493233
http://dx.doi.org/10.1186/s12885-020-06948-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267765/
https://www.ncbi.nlm.nih.gov/pubmed/32493233
http://dx.doi.org/10.1186/s12885-020-06948-5

Ejemplares similares